AMRI/PerkinElmer Collaboration Is Advancing Precision Medicine
Cookies on PerkinElmer
PerkinElmer uses cookies to ensure that we give you the best experience possible on our website. This may include cookies from third party websites. If you continue without changing your settings, we will assume that you consent to receive cookies from this website. You can change your cookie settings at any time. To learn more, please review our cookie policy, which includes information on how to manage your cookies.

AMRI/PerkinElmer Collaboration Is Advancing Precision Medicine

June 05, 2017

AMRI/PerkinElmer Collaboration Is Advancing Precision Medicine


To celebrate the opening of the Buffalo Medical Innovation and Commercialization Hub (BMIC) in Buffalo, NY, in 2015, PerkinElmer and Albany Molecular Research, Inc. (AMRI) pledged to work together to provide a range of comprehensive services to the regional medical and scientific community, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism, and pharmacokinetics.

Leveraging PerkinElmer

Two years into that collaboration, AMRI is making great strides forward by leveraging PerkinElmer’s cloud-based data management Signals Translational platform to aggregate research from a variety of sources and relate that data to meaningful scientific concepts, GEN Magazine reports.1

AMRI is creating data using a PerkinElmer cell::explorer® workstation. This robotic automation platform for cellular applications can analyze large, complex datasets from various translational platforms. The results are allowing AMRI to live up to its promise of sharing advanced translational data research with its BMIC partners and others as a means to accelerate the understanding of, and, in many cases, advance the drug discovery process.2

According to Jens Hoefkens, Director of Research, Strategic Marketing, Informatics for PerkinElmer, the PerkinElmer Signals Translational platform helps researchers integrate data from existing proprietary databases, and private and public databases such as GEO and tranSMART, and link with other enterprise systems. “It is a Software as a Service (SaaS) model that provides organizations with the flexibility and scalability they need to store structured and unstructured data, easily query, extract, identify and store information, and normalize the representation of stored data,” Hoefkens says.

Equally important is the Signals Translational platform emphasis on collaboration that is helping to break down traditional research and clinical data silos. As demonstrated by AMRI’s success in integrating big data tools to improve and share its research and development processes, it also marks an important step forward in advancing precision medicine by ensuring the best pairing between patients and drugs.

We are PerkinElmer … innovating and collaborating for a healthier world.


  1. Editors, “Big Data Sidebars,” GEN, January 15, 2017.
  2. Ibid.

Read More Stories Like This One

Breaking Down Biomarker Discovery: 5 Points

A biomarker, as defined by the National Cancer Institute, is a biological molecule found in blood, other bodily fluids, or tissues that is a sign of a normal or ...

Take Control of Nitrosamine Impurities

NDMA was found to be present not only in Valsartan but also in Ranitidine, as an impurity. However, in Ranitidine, it was found to have formed as a part of react...

The Why, Where and How of Live-Cell Imaging

Live-cell imaging enables researchers to study dynamic cellular processes, behaviour and function in real time and over time, giving a more complete and realisti...